Summary: Nyxoah SA has published 12-month safety and efficacy results from its DREAM pivotal study of the CE-marked Genio bilateral hypoglossal nerve stimulator. Median AHI reduction was 70.8% across all sleep positions and 66.6% in supine position at 12 months. These patients had a mean AHI of 28.0, mean ODI of 27.0, and mean body mass index of 28.5 at baseline. The publication also included previously announced data demonstrating similar AHI reduction in supine and non-supine positions. This reduction compares to a median 12-month AHI reduction of 70.8% across all sleeping positions.